Key terms
About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALKS news
Yesterday
10:06pm ET
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
Yesterday
10:35am ET
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Yesterday
6:32am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Yesterday
6:31am ET
Alkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline Prospects
Yesterday
5:17am ET
Maintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline Prospects
May 01
7:19am ET
Alkermes backs FY24 financial outlook
May 01
7:18am ET
Alkermes reports Q1 adjusted EPS 43c, consensus 58c
Apr 24
7:03am ET
Alkermes initiates Phase 2 clinical trial of ALKS 2680
Apr 19
6:30am ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
Apr 18
1:10am ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Apr 15
7:36am ET
Alkermes price target lowered to $23 from $25 at UBS
Apr 12
1:41am ET
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Apr 12
1:38am ET
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
Apr 11
11:20am ET
Biotech Alert: Searches spiking for these stocks today
Apr 09
8:55pm ET
Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential
Apr 09
1:05pm ET
Alkermes on the Rise: A Promising Outlook for Narcolepsy Treatment with ALKS 2680
Apr 09
12:15pm ET
Alkermes’s ALKS-2680 Shows Promising Efficacy in NT2, Enhancing Market Outlook and Supporting a Buy Rating
Apr 09
11:50am ET
Analysts Conflicted on These Healthcare Names: Chemed (CHE) and Alkermes (ALKS)
Apr 09
9:10am ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), LifeMD (LFMD) and Apyx Medical (APYX)
Apr 09
7:22am ET
Alkermes Reveals Promising Phase 1b Study Results
Apr 08
7:04am ET
Alkermes presents results from long-term safety study of LYBALVI
Apr 01
7:10am ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Opko Health (OPK) and Leafly Holdings, Inc. (LFLY)
Mar 27
5:55am ET
Alkermes management to meet with Piper Sandler
Mar 25
7:12am ET
Alkermes management to meet with Piper Sandler
Mar 18
4:29pm ET
Alkermes initiated with an Outperform at Baird
Mar 07
7:23am ET
Alkermes Expands Board, Elects Nancy Lurker as New Director
Feb 26
7:10am ET
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
Feb 20
7:01am ET
Alkermes downgraded to Sell from Neutral at UBS
Feb 18
11:46pm ET
Hold Rating on Alkermes Amid Competitive Uncertainty and Limited Growth Prospects
Feb 16
9:13am ET
Alkermes price target raised to $33 from $30 at BofA
Feb 16
8:35am ET
Alkermes price target raised to $39 from $35 at Piper Sandler
No recent press releases are available for ALKS
ALKS Financials
Key terms
Ad Feedback
ALKS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALKS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
